Supporting Healthcare Professionals in Advancing Patient Health with Sanofi

Investigational medicines, that is, medicines for which a marketing authorization application is ongoing or medicinal products which are not yet commercially available, may be used to treat certain people who are affected by life-threatening, long-lasting or seriously debilitating illnesses and are unable to participate in a clinical trial. Under certain circumstances, we make such medicines available to eligible patients.

Some people may benefit from an investigational product during a clinical trial, but don’t have access to the product once their participation has ended. That might be because it hasn’t been approved, or it is not yet on the market.

Under these circumstances and based on medical need, we may provide “post-trial access” to the experimental product.

Through our humanitarian programs for rare diseases and hemophilia, we support people throughout the world who have few or no treatment options.

We support bona fide research designed to advance science toward treatments that improve the standard of care. We receive, review, and respond to unsolicited proposals from health care professionals, scientists, and researchers or institutions (i.e. external sponsor) for research support.

Unsolicited proposals may be for Investigator Sponsored Studies (ISS) and Externally Sponsored Collaborations (ESC).